Description

Dihydroartemisinic Acid CAS NO 85031-59-0 is a key pharmaceutical intermediate and a direct biosynthetic precursor to the potent antimalarial compound artemisinin. Its significance lies in enabling the efficient, scalable semi-synthesis of artemisinin and its derivatives, which are critical for global malaria treatment. This high-purity intermediate is essential for manufacturers in the pharmaceutical and fine chemical sectors focused on producing life-saving antimalarial APIs and conducting related medicinal chemistry research.

Application

• Primary Intermediate for Artemisinin Synthesis: The most critical application is as a direct precursor in the chemical and enzymatic synthesis of artemisinin, a World Health Organization (WHO) essential medicine.
• Antimalarial API Production: Used in the commercial-scale manufacturing of artemisinin-based combination therapies (ACTs), which are the first-line treatment for *Plasmodium falciparum* malaria.
• Research & Development: Serves as a starting material in pharmaceutical R&D for synthesizing novel artemisinin derivatives and analogs with potential improved efficacy or new therapeutic applications.
• Fine Chemical Synthesis: Employed as a building block for synthesizing other sesquiterpene lactones and complex natural product analogs in advanced organic chemistry.
• Reference Standard: Used as a high-purity analytical standard in quality control laboratories for the identification and quantification of artemisinin and related compounds.

Basic Information

Product Name	Dihydroartemisinic Acid
CAS No.	85031-59-0
Molecular Formula	C15H24O2
Molecular Weight	236.35 g/mol
Synonyms	Dihydroartemisinic acid; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one; Artemisinic acid, dihydro-; (+)-Dihydroartemisinic acid; DHA; 85031-59-0
EINECS	Contact for details

Quality Control

Our Dihydroartemisinic Acid is produced under a strict quality management system. Each batch undergoes comprehensive analytical testing, including HPLC for purity and identity confirmation (IR, NMR), to ensure it meets the exacting standards required for pharmaceutical synthesis. We provide full traceability and a Certificate of Analysis (COA) with each shipment, detailing all critical quality attributes. Our processes are designed to support compliance with cGMP and other relevant regulatory frameworks for active pharmaceutical ingredient (API) manufacturing.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at controlled room temperature (15-25°C). Keep away from heat, open flames, and strong oxidizing agents. For long-term storage under an inert atmosphere (e.g., nitrogen or argon), please contact us for specific handling recommendations.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 1.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.